CLSI M100 S25 : 25ED 2015

Abstract
Committee Membership
Summary of Changes
Summary of CSLI Processes for Establishing Interpretive
Criteria and Quality Control Ranges
CLSI References Methods vs Commercial Methods
and CLSI vs US Food and Drug Administration
Interpretive Criteria (Breakpoints)
CLSI Breakpoint Additions/Revisions Since 2010
Subcommittee on Antimicrobial Susceptibility Testing
Mission Staement
Appendix A - Suggestions for Confirmation of Resistant (R),
             Intermediate (I), or Nonsuceptible (NS) Antimicrobial
             Susceptibility Test Result and Organism Identification
Appendix B - Intrinsic Resistance
Appendix C - Quality Control Strains for Antimicrobial
             Susceptibility Test
Appendix D - Cumulative Antimicrobial Susceptibility Report
             for Anaerobic Organisms
Appendix E - Dosing Regimens Used to Establish Susceptible
             or Susceptible-Dose Dependent Interpretive Criteria
Appendix F - Cefepime Breakpoint Change for Enterobacteriaceae
             and Introduction of the Susceptible- Dose Dependent
             Interpretive Category
Appendix G - Epidemiological Cutoff Values
The Quality Management System Approach
Related CLSI Reference Materials

Gives updates tables for the Clinical and Laboratory Standards Institute antimicrobial susceptibility testing Standards M02-A12, M07-A10, and M11-A8.